Best of 2022: Freeze Tag
Editor's note: this blog originally published on January 22, 2022, and is being shared again as a Best of 2022. Enjoy!
COVID-19 Vaccine Responses in Rheumatic Disease Patients
Nature Reviews Rheumatology features a review of three notable papers that address the impact of SARS-CoV-2 vaccination on people with inflammatory rheumatic disease.
Vaccine Efficacy in Patients with Seronegative Spondyloarthritis
Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.
Does Evusheld shield people living with rheumatic diseases?
Fast forward nearly 3 years since the first case of COVID-19 was reported, and I am amazed of the speed of response on how to keep our patients with rheumatic and musculoskeletal disease (RMD) safe from this infection.
Long COVID and Rheumatic Disease
The COVID-19 pandemic has had a significant impact worldwide particularly among those who are immunocompromised. Numerous studies have highlighted the increased risk of acute SARS-CoV-2 infection among patients with rheumatic diseases (RD).
Creaky Joints Presentations at ACR Convergence 2022
The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of these scientific posters.
Women with Rheumatic Disease (11.4.2022)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Undiagnosed RA During the Pandemic
EurekAlert!
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
Infections & Lupus (10.28.2022)
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
ACR Award Winners (10.21.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.
Vaccination Cut Long COVID Risk for Rheum Patients
MedPage Today
Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.
RheumNow Podcast – “That’s Not My Name” (10.7.2022)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.
Social
National French study finds post COVID Vaccine the IR of PMR (179 cases; RR 7.1/mill) & GCA (54 cases; RR 2.1 /million) were reported 7-10d post vax. These #s are below population incidence rates (1-20/mill for GCA) https://t.co/XvaoWhqs2g https://t.co/BFDy2WKcLx
Dr. John Cush @RheumNow ( View Tweet )
6 months 1 week ago
Machine learning analysis of retrosp EHR data (3/20-9/22) on 2+ million showed COVID (5.3%) outcomes in #IMID pts not linked to DMARD or IMID Dx; but rather to age, unvaccinated, & comorbidities (Afib, CAD, CHF, CKD, COPD, CA, liver Dz) https://t.co/aMmJD5P9cc https://t.co/Yy9FuCvol4
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
September 2023, CDC’s recommended the updated 2023–2024 booster COVID Vaccine (monovalent XBB.1.5). MMWR study shows only 18% of high risk (immunocompromised) recv'd it. Vax was 38% effective at preventing COVID hospitalization https://t.co/vf5jkMkPwj https://t.co/c55SuIuaDb
Dr. John Cush @RheumNow ( View Tweet )
7 months 4 weeks ago
Post-COVID POTS? Neurology cohort study of 16 pts - 81%F, mean age 36. Common Sxs:
- Palpitations & Fatuge in 2/3
- in <1/3: migraines, IBS, Raynaud’s
- Variable tilt test but High autonomic Sxs
No insights on Rx... https://t.co/I7MLjHAUDb https://t.co/hWnfJ9WWPX
Dr. John Cush @RheumNow ( View Tweet )
8 months ago
MMWR: Vaccination and Multisystem Inflammatory Syndrome in Children
MIS-C is a rare but serious condition typically occurring 2–6 weeks after SARS-CoV-2 infection and characterized by fever and multiorgan involvement.
https://t.co/PN2MPQxqSR https://t.co/eIzB4pjner
Dr. John Cush @RheumNow ( View Tweet )
8 months 1 week ago
COVIDs Extended Risk for Rheumatic Disease
Annals of Internal Medicine reports a large, binational study finding SARS-CoV-2 infection was associated with an increased risk for AIRDs that extends up to 12 months after infection.
https://t.co/HjQ56hiiny https://t.co/vvC3iVqNyF
Dr. John Cush @RheumNow ( View Tweet )
8 months 2 weeks ago
False positive COVID tests (+Rapid Ag; neg PCR) are rare, 1.7% of 11,297 tests; Persistent false positives seen in 13/191 and usually in women, with autoimmune dz (6/13; RA, SLE etc) & using the Quidel QuickVue rapid antigen test https://t.co/Pqkk7uBVcO https://t.co/m6ylQz00Ih
Dr. John Cush @RheumNow ( View Tweet )
9 months ago
Best Treatments for COVID-Related MIS-C
https://t.co/6Ntdug1eam https://t.co/x6de0DQTZ9
Dr. John Cush @RheumNow ( View Tweet )
10 months ago
Hydroxychloroquine for COVID may have caused 16,990 deaths. Systematic review of 44 cohort studies showed HCQ use in COVID was associated with 11% increase in mortality in 6 countries (US 12,739, Spain 1,895, Italy 1,822, Belgium 240, France 199,Turkey 95 https://t.co/vmhvSx4XLO https://t.co/KRxqiiSFC3
Dr. John Cush @RheumNow ( View Tweet )
10 months 2 weeks ago
🔥 HOT OFF THE PRESS for #ACR23
Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic autoimmune rheumatic diseases using DMARDs: an emulated target trial https://t.co/bvc75BP4aG @zach_wallace_md @jeffsparks https://t.co/CAlgjvUr9X
The Lancet Rheumatology @TheLancetRheum ( View Tweet )
1 year ago
